Den Europæiske Union - tysk - EMA (European Medicines Agency)

astra zeneca ab - saxagliptin, dapagliflozin propandiol monohydrat - diabetes mellitus, type 2; diabetes mellitus; nutritional and metabolic diseases; metabolic diseases; glucose metabolism disorders - drogen bei diabetes verwendet - qtern, fest-dosis-kombination von saxagliptin und dapagliflozin, ist indiziert bei erwachsenen im alter von 18 jahren und älter mit typ-2-diabetes mellitus:verbesserung der glykämischen kontrolle bei metformin und/oder sulphonylurea (su) und eine der monocomponents von qtern bieten keine adäquaten glykämischen kontrolle,wenn schon die behandlung mit der freien kombination von dapagliflozin und saxagliptin. (siehe abschnitt 4. 2, 4. 4, 4. 5 und 5. 1 für verfügbare daten über kombinationen untersucht.

Den Europæiske Union - tysk - EMA (European Medicines Agency)

astrazeneca ab - metformin hydrochlorid, saxagliptin, dapagliflozin - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - qtrilmet ist indiziert bei erwachsenen im alter von 18 jahren und älter mit typ-2-diabetes mellitus:verbesserung der glykämischen kontrolle bei metformin mit oder ohne sulphonylurea (su) und entweder saxagliptin oder dapagliflozin nicht ausreichender glykämischer kontrolle. wenn schon, behandelt mit metformin und saxagliptin und dapagliflozin.

Belgien - tysk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

as grindeks - sitagliptin hydrochloride monohydrate - filmtablette - 100 mg - sitagliptin hydrochloride monohydrate 113.4 mg - sitagliptin

Belgien - tysk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka, d.d. novo mesto - sitagliptin - filmtablette - 25 mg - sitagliptin 25 mg - sitagliptin

Belgien - tysk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka, d.d. novo mesto - sitagliptin - filmtablette - 50 mg - sitagliptin 50 mg - sitagliptin

Belgien - tysk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka, d.d. novo mesto - sitagliptin - filmtablette - 100 mg - sitagliptin 100 mg - sitagliptin

Den Europæiske Union - tysk - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Den Europæiske Union - tysk - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Belgien - tysk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eurogenerics afgekort "e.g." - sitagliptin hydrochloride - filmtablette - 25 mg - sitagliptin hydrochloride 27.238 mg - sitagliptin

Belgien - tysk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eurogenerics afgekort "e.g." - sitagliptin hydrochloride - filmtablette - 50 mg - sitagliptin hydrochloride 54.475 mg - sitagliptin